Advertisement

Novel nonsense IL-12Rβ1 mutation associated with recurrent tuberculosis

  • Noor ul Akbar
  • Shahid Niaz Khan
  • Muhammad Usman Amin
  • Muhammad Ishfaq
  • Otavio Cabral-Marques
  • Lena F Schimke
  • Asif Iqbal
  • Ikram Ullah
  • Mubashir Hussain
  • Ijaz Ali
  • Nasar Khan
  • Nadia El Khawanky
  • Hazir Rahman
  • Taj Ali KhanEmail author
Original Article

Abstract

The interleukin (IL)-12/interferon(IFN)γ axis plays an important role in the control of mycobacterial diseases as demonstrated by the increased susceptibility to mycobacterial species in patients with an inborn error of the IL-12-dependent IFNγ immunity. Here, we report a novel mutation in the IL-12Rβ1 gene in a female Pakistani patient who was born in a consanguineous marriage and developed severe bacille Calmette–Guérin (BCG) infection and recurrent tuberculosis. After reviewing the patient’s clinical records, she was investigated for IL-12/IFNγ defects using enzyme-linked immunosorbent assay (ELISA), flow cytometry, and DNA genetic Sanger sequencing. Quantification of secretory cytokines from the patient’s peripheral blood mononuclear cells (PBMCs) revealed significantly reduced IFNγ production. Flow cytometric analysis revealed no surface expression of IL-12Rβ1 on PHA-activated T lymphocytes. In addition, IL-12-induced impaired STAT4 phosphorylation in the patient’s lymphocytes when compared with those from five healthy controls. The genetic analysis of IL-12Rβ1 gene identified a novel nonsense mutation c.199G>T/p.E67* within exon 3, which encodes part of the cytokine-binding region (CBR). In silico analysis indicates that this novel nonsense mutation generates a truncated protein with an apparent inactivating effect. Our data expand the genetic spectrum of IL-12Rβ1 deficiency. Moreover, our findings highlight the need for developing newborn screening for patients with primary immunodeficiency associated with mycobacterial infections in areas where BCG vaccination is mandatory in order to improve the treatment of patients, and consequently their quality of life.

Keywords

IL-12Rβ1 Novel mutation IFNγ Tuberculosis 

Abbreviations

TB

Tuberculosis

IL

Interleukin

IFN

Interferon

BCG

Bacille Calmette–Guérin

CBR

Cytokine-binding region

NTM

Non-tuberculous mycobacteria

TYK

Tyrosine-protein kinase

JAK

Janus kinase

PIDs

Primary immunodeficiencies

SCID

Severe combined immunodeficiency

G6PD

Glucose-6-phosphate dehydrogenase

NEMO

NF-kappa B essential modulator

MSMD

Mendelian susceptibility to mycobacterial disease

FNIII

Fibronectin type-III domain

Notes

Compliance with ethical standards

The patient and healthy controls (all from Pakistan; mean age, 20 years old) provided written consent to participate in the study, and their blood sample was collected according to the institutional guidelines for functional and molecular characterization. The study was approved by the ethics committee of Kohat University of Science and Technology, Kohat, Pakistan.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57–72.  https://doi.org/10.1016/s0140-6736(10)62173-3.CrossRefPubMedGoogle Scholar
  2. 2.
    Khan AH. Tuberculosis control in Sindh, Pakistan: critical analysis of its implementation. J Infect Public Health. 2017;10(1):1–7.CrossRefGoogle Scholar
  3. 3.
    van de Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, Metin A, et al. IL-12 R β1 deficiency: mutation update and description of the IL 12 RB 1 variation database. Hum Mutat. 2013;34(10):1329–39.CrossRefGoogle Scholar
  4. 4.
    Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-γ production but not for cell proliferation. Proc Natl Acad Sci. 2002;99(19):12281–6.CrossRefGoogle Scholar
  5. 5.
    Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L, editors. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol. 2014;26(6):454–70.  https://doi.org/10.1016/j.smim.2014.09.008.CrossRefGoogle Scholar
  6. 6.
    Uciechowski P, Imhoff H, Lange C, Meyer CG, Browne EN, Kirsten DK, et al. Susceptibility to tuberculosis is associated with TLR1 polymorphisms resulting in a lack of TLR1 cell surface expression. J Leukoc Biol. 2011;90(2):377–88.  https://doi.org/10.1189/jlb.0409233.CrossRefPubMedGoogle Scholar
  7. 7.
    Berrington WR, Hawn TR. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter? Immunol Rev. 2007;219:167–86.  https://doi.org/10.1111/j.1600-065X.2007.00545.x.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lee W-I, Huang J-L, Yeh K-W, Jaing T-H, Lin T-Y, Huang Y-C, et al. Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs). J Formos Med Assoc. 2011;110(12):750–8.CrossRefGoogle Scholar
  9. 9.
    Bousfiha A, Jeddane L, Picard C, Ailal F, Gaspar HB, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRefGoogle Scholar
  10. 10.
    Khan TA, Iqbal A, Rahman H, Cabral-Marques O, Ishfaq M, Muhammad N. Novel RAG1 mutation and the occurrence of mycobacterial and Chromobacterium violaceum infections in a case of leaky SCID. Microb Pathog. 2017;109:114–9.CrossRefGoogle Scholar
  11. 11.
    Khan TA, Mazhar H, Nawaz M, Kalsoom K, Ishfaq M, Asif H, et al. Expanding the clinical and genetic spectrum of G6PD deficiency: the occurrence of BCGitis and novel missense mutation. Microb Pathog. 2017;102:160–5.CrossRefGoogle Scholar
  12. 12.
    de la Morena MT, Leonard D, Torgerson TR, Cabral-Marques O, Slatter M, Aghamohammadi A, et al. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. J Allergy Clin Immunol. 2017;139(4):1282–92.CrossRefGoogle Scholar
  13. 13.
    Cabral-Marques O, Klaver S, Schimke LF, Ascendino ÉH, Khan TA, Pereira PVS, et al. First report of the hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes. J Clin Immunol. 2014;34(2):146–56.CrossRefGoogle Scholar
  14. 14.
    Cabral-Marques O, Schimke L-F, Pereira PVS, Falcai A, de Oliveira JB, Hackett MJ, et al. Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients. J Clin Immunol. 2012;32(2):212–20.CrossRefGoogle Scholar
  15. 15.
    Khan TA, Schimke LF, Amaral EP, Ishfaq M, Barbosa Bonfim CC, Rahman H, et al. Interferon-gamma reduces the proliferation of M. tuberculosis within macrophages from a patient with a novel hypomorphic NEMO mutation. Pediatr Blood Cancer. 2016;63(10):1863–6.CrossRefGoogle Scholar
  16. 16.
    Al-Muhsen S, Casanova J-L. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol. 2008;122(6):1043–51.CrossRefGoogle Scholar
  17. 17.
    Ramirez-Alejo N, Santos-Argumedo L. Innate defects of the IL-12/IFN-gamma axis in susceptibility to infections by mycobacteria and salmonella. J Interf Cytokine Res. 2014;34(5):307–17.  https://doi.org/10.1089/jir.2013.0050.CrossRefGoogle Scholar
  18. 18.
    Boisson-Dupuis S, El Baghdadi J, Parvaneh N, Bousfiha A, Bustamante J, Feinberg J, et al. IL-12Rβ1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS One. 2011;6(4):e18524.CrossRefGoogle Scholar
  19. 19.
    Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K. The World Health Organization standards for tuberculosis care and management. Eur Respir J 2018;51:1800098.  https://doi.org/10.1183/13993003.00098-2018.CrossRefGoogle Scholar
  20. 20.
    Schimke LF, Hibbard J, Martinez-Barricarte R, Khan TA, de Souza CR. Borges de Oliveira Junior E et al. Paracoccidioidomycosis associated with a heterozygous STAT4 mutation and impaired IFN-γ immunity. J Infect Dis. 2017;216(12):1623–34.CrossRefGoogle Scholar
  21. 21.
    Jirapongsananuruk O, Luangwedchakarn V, Niemela JE, Pacharn P, Visitsunthorn N, Thepthai C, et al. Cryptococcal osteomyelitis in a child with a novel compound mutation of the IL12RB1 gene. Asian Pac J Allergy Immunol. 2012;30(1):79–82.PubMedGoogle Scholar
  22. 22.
    Xu Y, Kershaw NJ, Luo CS, Soo P, Pocock MJ, Czabotar PE, et al. Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. J Biol Chem. 2010.  https://doi.org/10.1074/jbc.C110.129502.CrossRefGoogle Scholar
  23. 23.
    Iqbal A, Goldfeder MB, Marques-Porto R, Asif H, de Souza JG, Faria F, et al. Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin. Sci Rep. 2017;7(1):1431.CrossRefGoogle Scholar
  24. 24.
    Iqbal A, Azim MK. Structural bioinformatics of enol pyruvyl shikimate phosphate synthase from Vibrio cholerae. J Chem Soc Pak. 2012;34(1):120–6.Google Scholar
  25. 25.
    Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(suppl_2):W407–W10.CrossRefGoogle Scholar
  26. 26.
    Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26(2):283–91.CrossRefGoogle Scholar
  27. 27.
    van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis. 2004;4(12):739–49.CrossRefGoogle Scholar
  28. 28.
    Feinberg J, Fieschi C, Doffinger R, Feinberg M, Leclerc T, Boisson-Dupuis S, et al. Bacillus Calmette Guérin triggers the IL-12/IFN-γ axis by an IRAK-4-and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur J Immunol. 2004;34(11):3276–84.CrossRefGoogle Scholar
  29. 29.
    Fieschi C, Bosticardo M, De Beaucoudrey L, Boisson-Dupuis S, Feinberg J, Santos OF, et al. A novel form of complete IL-12/IL-23 receptor β1 deficiency with cell surface-expressed nonfunctional receptors. Blood. 2004;104(7):2095–101.CrossRefGoogle Scholar
  30. 30.
    van de Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, Metin A, et al. IL-12Rβ1 deficiency: mutation update and description of the IL12RB1 variation database. Hum Mutat. 2013;34(10):1329–39.  https://doi.org/10.1002/humu.22380.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–46.CrossRefGoogle Scholar
  32. 32.
    Caragol I, Raspall M, Fieschi C, Feinberg J, Larrosa MN, Hernández M, et al. Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor β1 deficiency. Clin Infect Dis. 2003;37(2):302–6.CrossRefGoogle Scholar
  33. 33.
    de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280(5368):1435–8.CrossRefGoogle Scholar
  34. 34.
    Altare F, Durandy A, Lammas D, Emile J-F, Lamhamedi S, Le Deist F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998;280(5368):1432–5.CrossRefGoogle Scholar
  35. 35.
    de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine. 2010;89(6):381–402.CrossRefGoogle Scholar
  36. 36.
    Hussain R, Bittles A. The prevalence and demographic characteristics of consanguineous marriages in Pakistan. J Biosoc Sci. 1998;30(2):261–75.CrossRefGoogle Scholar
  37. 37.
    Picard C, Fieschi C, Altare F, Al-Jumaah S, Al-Hajjar S, Feinberg J, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet. 2002;70(2):336–48.CrossRefGoogle Scholar
  38. 38.
    Khan T, Cabral-Marques O, Schimke L, de Oliveira JE, Amaral E, D’Império LM, et al. Tuberculosis in an autosomal recessive case of chronic granulomatous disease due to mutation of the NCF1 gene. Allergol Immunopathol. 2016;44(3):276.CrossRefGoogle Scholar
  39. 39.
    Cabral-Marques O, Ramos RN, Schimke LF, Khan TA, Amaral EP, Bomfim CCB, et al. Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-γ. J Allergy Clin Immunol. 2017;139(3):900–12. e7.CrossRefGoogle Scholar
  40. 40.
    de Oliveira-Junior EB, Zurro NB, Prando C, Cabral-Marques O, Pereira PVS, Schimke LF, et al. Clinical and genotypic spectrum of chronic granulomatous disease in 71 Latin American patients: first report from the LASID registry. Pediatr Blood Cancer. 2015;62(12):2101–7.CrossRefGoogle Scholar
  41. 41.
    Suárez-Méndez R, García-García I, Fernández-Olivera N, Valdés-Quintana M, Milanés-Virelles MT, Carbonell D, et al. Adjuvant interferon gamma in patients with drug–resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis. 2004;4(1):44.CrossRefGoogle Scholar
  42. 42.
    Boisson-Dupuis S, El Baghdadi J, Parvaneh N, Bousfiha A, Bustamante J, Feinberg J, et al. IL-12Rbeta1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS One. 2011;6(4):e18524.  https://doi.org/10.1371/journal.pone.0018524.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu C-Y, et al. A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits. Proc Natl Acad Sci. 1996;93(24):14002–7.CrossRefGoogle Scholar
  44. 44.
    Shami S. Risks in consanguineous marriages: an isonymic study. J Pak Med Assoc. 1981;31(12):269–76.PubMedGoogle Scholar
  45. 45.
    Hasan Z, Irfan M, Khan JA, Jahangir SK, Haris M, Ashraf M, et al. BCG vaccination is associated with decreased severity of tuberculosis in Pakistan. Int J Mycobacteriol. 2012;1(4):201–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Noor ul Akbar
    • 1
  • Shahid Niaz Khan
    • 1
  • Muhammad Usman Amin
    • 2
  • Muhammad Ishfaq
    • 3
  • Otavio Cabral-Marques
    • 4
  • Lena F Schimke
    • 4
  • Asif Iqbal
    • 5
  • Ikram Ullah
    • 6
  • Mubashir Hussain
    • 7
  • Ijaz Ali
    • 8
  • Nasar Khan
    • 9
  • Nadia El Khawanky
    • 10
    • 11
  • Hazir Rahman
    • 12
  • Taj Ali Khan
    • 7
    Email author
  1. 1.Department of ZoologyKohat University of Science and TechnologyKohatPakistan
  2. 2.Department of PharmacyAbasyn UniversityPeshawarPakistan
  3. 3.Centre for Omic SciencesIslamia College UniversityPeshawarPakistan
  4. 4.Center for Chronic Immunodeficiency (CCI), Medical Center – University of Freiburg, Faculty of MedicineUniversity of FreiburgFreiburg im BreisgauGermany
  5. 5.Department of PharmacologyUniversity of Illinois at ChicagoChicagoUSA
  6. 6.Suliman Bin Aba-Alkhail Center for Interdisciplinary Research in Basic Sciences (SA-CIRBS)International Islamic UniversityIslamabadPakistan
  7. 7.Department of MicrobiologyKohat University of Science and TechnologyKohatPakistan
  8. 8.Department of BiosciencesCOMSATS University IslamabadIslamabadPakistan
  9. 9.Interdisciplinary Nanoscience CenterAarhus UniversityAarhusDenmark
  10. 10.Department of Hematology, Oncology and Stem Cell TransplantationFreiburg University Medical CenterFreiburgGermany
  11. 11.Precision Medicine ThemeThe South Australian Health and Medical Research Institute (SAHMRI)AdelaideAustralia
  12. 12.Department of Microbiology, Faculty of Health SciencesAbdul Wali Khan University Mardan (AWKUM)MardanPakistan

Personalised recommendations